![A worker in a lab.](https://assets.technologynetworks.com/production/dynamic/images/content/380981/glox-therapeutics-secures-43m-seed-funding-to-develop-precision-antimicrobials-targeting-drug-380981-640x360.jpg?cb=12554462)
Product News
Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria
Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
![A scientist behind a screen.](https://assets.technologynetworks.com/production/dynamic/images/content/380871/armis-biopharma-announces-receipt-of-a-203-million-contract-with-the-defense-threat-reduction-380871-640x360.jpg?cb=12548719)
Product News
Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds
Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.
![A frozen Eppendorf tube held with tweezers.](https://assets.technologynetworks.com/production/dynamic/images/content/380404/modelling-enables-breakthroughs-in-neuromuscular-disease-research-380404-640x360.jpg?cb=12532880)
Product News
Modelling Enables Breakthroughs in Neuromuscular Disease Research
A team of scientists have developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s).
![An outsretched palm holding an assortment of different pills.](https://assets.technologynetworks.com/production/dynamic/images/content/380353/pharmakure-submits-mhra-cta-for-phase-2a-clinical-trial-of-pk051-in-patients-with-mild-cognitive-380353-640x360.jpg?cb=12528505)
Product News
PharmaKure Submits Mhra CTA for Phase 2a Clinical Trial of PK051 in Patients With Mild Cognitive Impairment
Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.
![An individual sitting at a table with their laptop open.](https://assets.technologynetworks.com/production/dynamic/images/content/380348/optibrium-introduces-cloud-based-version-of-stardrop-drug-discovery-platform-380348-640x360.jpg?cb=12528500)
Product News
Optibrium Introduces Cloud-Based Version of StarDrop Drug Discovery Platform
Optibrium, announced that its drug discovery platform, StarDrop, is now also available in the cloud environment.
![A scientist pipetting into an Eppendorf tube.](https://assets.technologynetworks.com/production/dynamic/images/content/380037/new-mid-term-guidance-2024-2028-supported-by-ramp-up-of-growth-projects-380037-640x360.jpg?cb=12516967)
Product News
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day in Visp (CH), Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.
![Orange and white capsules spilling out of a plastic pill bottle.](https://assets.technologynetworks.com/production/dynamic/images/content/379936/phesi-launches-health-check-and-trial-rescue-service-to-save-at-risk-trials-and-bring-drugs-to-379936-640x360.jpg?cb=12514081)
Product News
Phesi Launches Health Check and Trial Rescue Service To Save At-Risk Trials and Bring Drugs to Market Faster
New free of charge service will offer insights in under ten days to sponsors conducting clinical trials in any indication, identifying potential “zombie trials” and providing actionable recommendations for failing trials.
![A drug capsule cut in half with drug molecules revealing from inside.](https://assets.technologynetworks.com/production/dynamic/images/content/379883/halozyme-announces-positive-clinical-data-of-its-high-volume-auto-injector-379883-640x360.jpg?cb=12512643)
Product News
Halozyme Announces Positive Clinical Data of Its High Volume Auto-Injector
Study met primary endpoint and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme’s proprietary high-volume auto-injector.
![Bio-Rad Anti-dupilumab Antibodies.](https://assets.technologynetworks.com/production/dynamic/images/content/379671/bio-rad-extends-range-of-anti-idiotypic-antibodies-for-use-in-preclinical-and-clinical-drug-379671-640x360.jpg?cb=12504002)
Product News
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development
Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.
![Antibodies.](https://assets.technologynetworks.com/production/dynamic/images/content/379659/lonza-further-extends-collaboration-with-major-biopharmaceutical-partner-for-manufacturing-antibody-379659-640x360.jpg?cb=12502670)
Product News
Lonza Further Extends Collaboration With Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.
Advertisement